Ken Griffin Vera Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$34.09 - $46.71 $129,542 - $177,498	3,800 Added 158.33%	6,200 $273,000
Q2 2024 Aug 14, 2024	SELL	$33.72 - $48.82 $198,948 - $288,038	-5,900 Reduced 71.08%	2,400 $86,000
Q1 2024 May 15, 2024	BUY	$14.91 - $49.14 $67,095 - $221,130	4,500 Added 118.42%	8,300 $357,000
Q4 2023 Feb 14, 2024	SELL	$9.29 - $16.0 $58,526 - $100,800	-6,300 Reduced 62.38%	3,800 $58,000
Q3 2023 Nov 14, 2023	SELL	$13.71 - $19.64 $74,034 - $106,056	-5,400 Reduced 34.84%	10,100 $138,000
Q2 2023 Aug 14, 2023	BUY	$6.11 - $17.83 $58,045 - $169,384	9,500 Added 158.33%	15,500 $248,000
Q1 2023 May 15, 2023	BUY	$5.41 - $18.3 $32,460 - $109,800	6,000 New	6,000 $46,000

184

55.1M

134K

156K

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.28B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.